__NUXT_JSONP__("/drugs/Avapritinib", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"Ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.",inn:b,marketingAuthorisationDate:"2020-09-24 00:00:00",marketingAuthorisationHolder:"Blueprint Medicines (Netherlands) B.V.",medicineName:"Ayvakyt",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fayvakyt"}],fdaDrugLabel:[{brand:"Ayvakit",indication:"1 INDICATIONS AND USAGE AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.1 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 \u002FL ( 1.2 ) 1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT™ is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations [see Dosage and Administration (2.1) ] . 1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 \u002FL [see Warnings and Precautions (5.1) ] .",manufacturer:"Blueprint Medicines Corporation",splSetId:"645c887c-8cd4-4623-8da9-ac223d71a8b9"}],id:a,nciThesaurus:{casRegistry:"1703793-34-3",chebiId:c,chemicalFormula:c,definition:"An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast\u002Fstem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases and tumor-associated antigens (TAAs), are mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation.",fdaUniiCode:"513P80B4YJ",identifier:"C123827",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C159198","C159199"],synonyms:["(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine","AVAPRITINIB","AYVAKIT",a,"BLU-285","CS3007","PDGFR alpha\u002FKIT Mutant-specific Inhibitor BLU-285"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAvapritinib",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Avapritinib","avapritinib","","2021-10-30T13:30:07.123Z")));